Inventiva S.A. ADR (IVA)

Apr 1, 2025, 5:00 PM EDT - 2 days ago

Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis

Mar 27, 2025, 10:50 AM EDT - 8 days ago

Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript

Mar 26, 2025, 4:00 PM EDT - 8 days ago

Inventiva reports its 2024 full year results and provides a business update

Mar 19, 2025, 4:00 PM EDT - 15 days ago

Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

Feb 26, 2025, 4:00 PM EST - 5 weeks ago

Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment

Feb 20, 2025, 4:00 PM EST - 6 weeks ago

Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial

Feb 10, 2025, 4:00 PM EST - 7 weeks ago

Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update

Jan 29, 2025, 4:00 PM EST - 2 months ago

Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology

Jan 24, 2025, 4:00 PM EST - 2 months ago

Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux

Jan 22, 2025, 4:00 PM EST - 2 months ago

Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025

Dec 17, 2024, 4:00 PM EST - 3 months ago

Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 16, 2024, 2:30 AM EST - 3 months ago

Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million

Dec 12, 2024, 4:00 PM EST - 4 months ago

Results of the votes of the Combined Shareholders' General Meeting of December 11, 2024

Nov 21, 2024, 4:00 PM EST - 4 months ago

Inventiva reports 2024 Third Quarter Financial Information¹

Nov 20, 2024, 4:00 PM EST - 4 months ago

Combined General Meeting of December 11, 2024 - Availability of the preparatory documents

Nov 18, 2024, 8:30 AM EST - 4 months ago

Alight to Enhance the Employee Experience with Launch of Alight Worklife® on Microsoft Teams

ALIT

Nov 15, 2024, 4:00 PM EST - 4 months ago

Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session

Oct 30, 2024, 4:00 PM EDT - 5 months ago

Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH

Oct 21, 2024, 8:30 AM EDT - 5 months ago

Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024

Oct 14, 2024, 1:45 PM EDT - 6 months ago

Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants

Oct 14, 2024, 10:48 AM EDT - 6 months ago

Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday?

Oct 14, 2024, 2:35 AM EDT - 6 months ago

Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report

Oct 14, 2024, 2:30 AM EDT - 6 months ago

Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study

Sep 25, 2024, 4:00 PM EDT - 6 months ago

Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results

Jul 31, 2024, 4:00 PM EDT - 8 months ago

Inventiva Reports Preliminary 2024 First-Half Financial Information¹

Jul 25, 2024, 4:00 PM EDT - 9 months ago

Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor

Jul 18, 2024, 2:30 AM EDT - 9 months ago

Inventiva announces a €20.1 million issuance of royalty certificates

Jul 8, 2024, 2:36 PM EDT - 9 months ago

Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement

Jul 5, 2024, 4:00 PM EDT - 9 months ago

Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position

Jun 21, 2024, 4:00 PM EDT - 10 months ago

Results of the votes of the Combined Shareholders' General Meeting of June 20, 2024

May 30, 2024, 2:30 AM EDT - 11 months ago

Combined General Meeting of June 20, 2024 - Availability of the preparatory documents

May 22, 2024, 4:00 PM EDT - 11 months ago

Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024

May 21, 2024, 4:00 PM EDT - 11 months ago

Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update

May 16, 2024, 4:00 PM EDT - 11 months ago

Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH

May 13, 2024, 2:30 AM EDT - 11 months ago

Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor

Apr 3, 2024, 4:00 PM EDT - 1 year ago

Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F

Mar 28, 2024, 11:27 AM EDT - 1 year ago

Inventiva S.A. (IVA) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 3:00 AM EDT - 1 year ago

Inventiva announces the nomination of Andre Turenne as Director

Mar 27, 2024, 4:00 PM EDT - 1 year ago

Inventiva reports its 2023 full-year results

Mar 22, 2024, 4:00 PM EDT - 1 year ago

Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results

Mar 18, 2024, 4:00 PM EDT - 1 year ago

Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D

Mar 13, 2024, 4:00 PM EDT - 1 year ago

Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D

Mar 7, 2024, 4:00 PM EST - 1 year ago

Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed

Feb 22, 2024, 4:50 PM EST - 1 year ago

Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause

Feb 15, 2024, 4:35 PM EST - 1 year ago

Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3

Jan 10, 2024, 4:00 PM EST - 1 year ago

Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank

Dec 20, 2023, 4:00 PM EST - 1 year ago

Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program

Dec 4, 2023, 4:05 PM EST - 1 year ago

Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH

Nov 21, 2023, 4:00 PM EST - 1 year ago

Inventiva reports 2023 Third Quarter Financial Information¹

Nov 6, 2023, 4:00 PM EST - 1 year ago

Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023